Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan (Scientific Reports, (2016), 6, 1, (36482), 10.1038/srep36482);Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Xifeng ^a   Wen, Chi Pang ^b,c   Ye, Yuanqing ^a   Tsai, MinKwang ^b,c   Wen, Christopher ^a   Roth, Jack A ^d   Pu, Xia ^a   Chow, Wong Ho ^a   Huff, Chad ^a   Cunningham, Sonia ^a   Huang, Maosheng ^a   Wu, Shuanbei ^b,c   Tsao, Chwen Keng ^e   Gu, Jian ^a   Lippman, Scott M ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MJ Health Management Institution   (Taiwan)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN;

AGED; AREA UNDER THE CURVE; BLOOD; COHORT ANALYSIS; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; LUNG FUNCTION TEST; LUNG TUMOR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PUBLIC HEALTH; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICS AND NUMERICAL DATA; TAIWAN; X-RAY COMPUTED TOMOGRAPHY;

AGED; ALPHA-FETOPROTEINS; AREA UNDER CURVE; BILIRUBIN; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATIONAL HEALTH PROGRAMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SMOKERS; TAIWAN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84994386046     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-62322-2     Document Type: Erratum

References (24)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90, doi: 10.3322/caac.20107 (2011).
2. Chiang, C. J., Chen, Y. C., Chen, C. J., You, S. L. & Lai, M. S. Cancer trends in Taiwan. Jpn J Clin Oncol 40, 897-904, doi: 10.1093/jjco/hyq057 (2010).
3. Chin, L. et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527-538 (1999).
4. Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365, 395-409, doi: 10.1056/NEJMoa1102873 (2011).
5. Pinsky, P. F. & Berg, C. D. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen 19, 154-156, doi: 10.1258/jms.2012.012010 (2012).
6. McRonald, F. E. et al. The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening. Cancer Prev Res (Phila) 7, 362-371, doi: 10.1158/1940-6207.CAPR-13-0206 (2014).
7. Jaklitsch, M. T. et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. The Journal of thoracic and cardiovascular surgery 144, 33-38, doi: 10.1016/j.jtcvs.2012.05.060 (2012).
8. Field, J. K. et al. The contribution of risk prediction models to early detection of lung cancer. J Surg Oncol 108, 304-311, doi: 10.1002/jso.23384 (2013).
9. Bach, P. B. et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 95, 470-478 (2003).
10. Spitz, M. R. et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 99, 715-726, doi: 10.1093/jnci/djk153 (2007).
11. Cassidy, A. et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 98, 270-276, doi: 10.1038/sj.bjc.6604158 (2008).
12. Tammemagi, C. M. et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 103, 1058-1068, doi: 10.1093/jnci/djr173 (2011).
13. Hoggart, C. et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila) 5, 834-846, doi: 10.1158/1940-6207.CAPR-11-0237 (2012).
14. Tammemagi, M. C. et al. Selection criteria for lung-cancer screening. N Engl J Med 368, 728-736, doi: 10.1056/NEJMoa1211776 (2013).
15. Wasswa-Kintu, S., Gan, W. Q., Man, S. F. P., Pare, P. D. & Sin, D. D. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 60, 570-575, doi: 10.1136/thx.2004.037135 (2005).
16. Grunnet, M. & Sorensen, J. B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76, 138-143, doi: 10.1016/j.lungcan.2011.11.012 (2012).
17. Patz, E. F. et al. Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology 25, 5578-5583, doi: 10.1200/Jco.2007.13.5392 (2007).
18. Bertino, G. et al. Hepatocellualar carcinoma serum markers. Semin Oncol 39, 410-433, doi: 10.1053/j.seminoncol.2012.05.001 (2012).
19. Guo, Y. Z., Pan, L., Du, C. J., Ren, D. Q. & Xie, X. M. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pacific journal of cancer prevention: APJCP 14, 243-248 (2013).
20. Shiels, M. S. et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 105, 1871-1880, doi: 10.1093/jnci/djt309 (2013).
21. Horsfall, L. J. et al. Serum bilirubin and risk of respiratory disease and death. JAMA: the journal of the American Medical Association 305, 691-697, doi: 10.1001/jama.2011.124 (2011).
22. D'Amelio, A. M. Jr. et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 103, 423-429, doi: 10.1038/sj.bjc.6605759 (2010).
23. Wen, C. P. et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371, 2173-2182, doi: 10.1016/S0140-6736(08)60952-6 (2008).
24. Sullivan, L. M., Massaro, J. M. & D'Agostmo, R. B. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23, 1631-1660, doi: Doi 10.1002/Sim.1742 (2004).